Previous Article | Next Article 
Journal of Virology, July 2001, p. 5778-5795, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5778-5795.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
The Major Core Protein P4a (A10L Gene) of Vaccinia
Virus Is Essential for Correct Assembly of Viral DNA into the
Nucleoprotein Complex To Form Immature Viral Particles
Ritva
Heljasvaara,1
Dolores
Rodríguez,1
Cristina
Risco,2
José L.
Carrascosa,2
Mariano
Esteban,1,* and
Juan Ramón
Rodríguez1
Departments of Molecular and Cellular
Biology1 and Macromolecular
Structure,2 Centro Nacional de
Biotecnología, Consejo Superior de Investigaciones
Cientifícas, Campus Universidad Autónoma, Cantoblanco,
28049 Madrid, Spain
Received 28 July 2000/Accepted 2 April 2001
 |
ABSTRACT |
The vaccinia virus (VV) A10L gene codes for a major core protein,
P4a. This polypeptide is synthesized at late times during viral
infection and is proteolytically cleaved during virion assembly. To
investigate the role of P4a in the virus life cycle and morphogenesis, we have generated an inducer-dependent conditional mutant (VVindA10L) in which expression of the A10L gene is under the control of the Escherichia coli lacI operator/repressor system. Repression
of the A10L gene severely impairs virus growth, as observed by both the
inability of the virus to form plaques and the 2-log reduction of viral
yields. This defect can be partially overcome by addition of the
inducer isopropyl-
-D-thiogalactopyranoside (IPTG).
Synthesis of viral proteins other than P4a occurred, although early
shutoff of host protein synthesis and expression of viral late
polypeptides are clearly delayed, both in the absence and in the
presence of IPTG, compared with cells infected with the parental virus.
Viral DNA replication and concatemer resolution appeared to proceed normally in the absence of the A10L gene product. In cells infected with VVindA10L in the absence of the inducer virion assembly is blocked, as defined by electron microscopy. Numerous spherical immature
viral particles that appear devoid of dense viroplasmic material
together with highly electron-dense regular structures are abundant in
VVindA10L-infected cells. These regularly spaced structures can be
specifically labeled with anti-DNA antibodies as well as with a
DNase-gold conjugate, indicating that they contain DNA. Some images
suggest that these DNA structures enter into spherical immature viral
particles. In this regard, although it has not been firmly established,
it has been suggested that DNA uptake occurs after formation of
spherical immature particles. Overall, our results showed that P4a
and/or its cleaved products are essential for the correct assembly of
the nucleoprotein complex within immature viral particles.
 |
INTRODUCTION |
Vaccinia virus (VV), the
prototype member of the Poxviridae family, is a large DNA
virus whose replication and assembly occur entirely in the cytoplasm of
the host cell, in particular areas termed viral factories or virosomes
(33). The linear double-stranded DNA genome has a capacity
to encode over 200 polypeptides (22), of which
approximately 100 are incorporated into virus particles (14). The viral genes can be divided into three classes
according to their temporally regulated expression. The early genes are transcribed prior to DNA replication, while the intermediate and late
genes are transcribed only during or after replication of the viral
genome (33).
Detailed information about VV morphogenesis has been obtained from
studies by conventional electron microscopy (6, 7, 9, 21, 31,
32). Virus assembly begins within cytoplasmic viral factories
with the formation of crescent-shaped membranes whose origin remains
controversial. These membranes subsequently enclose granular material
from the virosomes, forming spherical particles known as immature
virions (IVs). The IVs undergo additional maturation events,
transforming into brick-shaped structures where the envelope surrounds
an electron-dense core structure containing viral DNA. These virions
constitute the first infectious form of VV, and they are referred to as
intracellular mature virions (IMVs). A small portion of IMVs become
wrapped by a membrane cisterna derived from the trans-Golgi
network (50). These intracellular enveloped virions are
released from the cell by fusion with the plasma membrane, a process
whereby they lose the outermost membrane. The resulting extracellular
enveloped virions are largely responsible for virus spread both in
tissue culture and in animals (3, 37).
The complex morphological changes that occur during the transition from
IV to IMV are poorly understood (33). After successful DNA
replication and concatemer resolution (11, 30, 35), the
viral genome is condensed and packaged as a nucleoprotein complex in
the IVs (31, 32). Other events implicated in virus maturation include assembly and encapsidation of a multiprotein transcription complex (69), proteolytic processing of
major structural proteins (25, 26, 34, 55, 56, 65),
formation of a defined core (18, 32), and reorganization
of viral membranes (5, 32). Studies with
temperature-sensitive (ts) and inducible VV mutants have
revealed that several proteins interacting with DNA are involved in
transition from IV to IMV. Thus, the core protein VP8 (L4R) is thought
to be required for correct packaging of the viral genome and/or for the
efficient transcription of DNA (61), whereas DNA-binding
phosphoprotein VP11 (F18R) (67) and the I7 protein,
homologous to yeast type II DNA topoisomerase (24), appear
to be essential for nucleoid condensation. The A32 protein appears to
be required at an earlier step, since repression of A32 results in the
accumulation of DNA-deficient IVs (4). Also other
DNA-binding proteins, such as the VV early transcription factor VETF,
composed of two subunits encoded by the D6R and A8L genes, and the
product of the I1L gene are needed for IV-to-IMV transition since
viruses deficient in these polypeptides are blocked at the IV stage
(19, 20, 27, 29). A similar phenotype is displayed when
synthesis of the two structural proteins 39K (A5L) (63)
and L1R (38), present in the core and envelope, respectively, is prevented. Proteolytic cleavage of major core proteins
P4a (A10L), P4b (A3L), and VP8, which occurs at a late stage of core
formation, is apparently required for production of infectious mature
virions. Drugs that block virus assembly, such as rifampin and
novobiocin, also inhibit the proteolytic processing of these core
polypeptides (25, 51). The failure in processing is
believed to be an effect secondary to the block in immature envelope
formation, which leads to interruption of later stages of viron
morphogenesis (25, 68). Repression of the D13L gene,
coding for the p65 membrane-associated protein, mimics the effects of
rifampin and prevents both viral assembly and protein cleavage
(68).
Among the most abundant structural components of the VV is the major
core protein P4a, which alone accounts for approximately 14% of the
particle's dry weight (49). The 4a polypeptide is a
processing product of a higher-molecular-weight precursor P4a (24), which is encoded by the A10L gene (54,
62). P4a is synthesized at late times in the viral infection as
a 102-kDa protein, which is posttranslationally cleaved to two smaller
polypeptides. The processing occurs at two locations: cleavage at the
N-terminal Ala-Gly-Ser site between amino acids 614 and 615 and
cleavage at the C-terminal Ala-Gly-Thr site between amino acids 697 and 698 lead to release of 62-kDa (4a) and 23-kDa polypeptides,
respectively (55, 56, 59). These cleavage sites are
distinct but related to the consensus Ala-Gly-Ala motif for the
proteolytic maturation of other VV structural proteins
(58). The precursor protein P4a is localized to viral
factories and immature virus particles, and both of the cleavage
products are associated with the core structure of the mature virion
(55, 57). Processing of P4a at these sites should
theoretically also yield an intervening 9-kDa polypeptide (amino acids
615 to 697), but its possible localization and fate remain unclear. We
have recently described that in the virion, the mature 4a protein forms
a complex with the 39K core protein, the product of A5L gene
(41), and this interaction may be crucial for the assembly
of the core structure.
To investigate the role of the major core protein P4a in VV assembly
and life cycle, we have constructed and characterized a conditional
virus mutant in which expression of the A10L gene is regulated by the
Escherichia coli lacI operator-repressor system. By
biochemical and electron microscopy analysis, we have defined that this
protein is required for correct assembly of the nucleoprotein complex
within IVs.
 |
MATERIALS AND METHODS |
Cells and viruses.
African green monkey kidney (BSC-40)
cells and HeLa cells were grown in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% newborn calf serum. VV strain Western
Reserve (WR) was propagated and titrated in BSC-40 cells. Recombinant
virus VVindA10L was grown in BSC-40 cells in the presence of 5 mM
isopropyl-
-D-thiogalactopyranoside (IPTG). Viral stocks
were partially purified by ultracentrifugation through a 45% sucrose
cushion. Further purification of viral particles was performed by
banding through 20 to 45% sucrose gradients (15). VVlacI
was previously described (42).
Antisera.
The rabbit polyclonal anti-P4a (referred to in
previous work as anti-62K), 14K, 39K, 15K, and 21K protein sera have
been previously described (12, 44, 46), as has the
polyclonal serum raised against live VV (45). Rabbit
polyclonal antisera against P4b and VP8 were kindly provided by D. Hruby (University of Oregon). A polyclonal serum against the 65K
protein was raised by immunization of a rabbit with a synthetic peptide
corresponding to amino acids 536 to 550 coupled to keyhole limpet
hemocyanin (this peptide was chosen based on the sequence of peptide B1
used by Sodeik et al. [52]). The gold-conjugated goat
anti-rabbit serum was purchased from Biocell (Cardiff, United Kingdom).
Plasmid construction.
For construction of plasmid transfer
vector popA10L-gpt, where the E. coli lac
operator is inserted immediately downstream of the endogenous A10L gene
promoter, two DNA fragments were amplified from VV strain WR (WR VV)
genomic DNA by PCR. PCR was performed with primers 1 (5'-CGGCCCGGGATGATG-CCTATTAAGTCAATAGTTAC-3' [translation initiation codon for A10L shown in boldface]), 2 (5'-CGCGAATTCTTTTATTGGTGCATTAATAACATCC-3'), 3 (5'-CGCGGATCCTTTTATCTTTATCATAAACTACTCC-3'), and
4 (5'-CGGCCCGGGAATTGTTATCCGCTCACAATTATTTATTTAGTATTAAATGACGACCG [lac operator sequence shown in boldface; conserved
sequence element TAAAT for transcription initiation of VV late genes
{10} shown underlined]). Primers 1 and 2 were used to
generate a DNA fragment containing 570 bp of the A10L open reading
frame (ORF) (amino acids 1 to 190) flanked by EcoRI and
SmaI restriction sites (restriction sites underlined in
primer sequences). Another DNA fragment consisting of VV A11R sequence
(amino acids 1 to 152), the entire promoter region between the A10L and
A11R ORFs, and E. coli lac operator sequence (21 bp),
flanked by SmaI and BamHI sites, was synthesized using primers 3 and 4. These two PCR-amplified fragments were sequentially cloned into pUC118. The coding sequence for the E. coli gpt gene under the VV p7.5 early/late promoter was amplified using primers
5'-TGCAAGCTTTAAATAATAAATACAATAATTAATTTCTCG-3'
and 5'-ATCAAGCTTTTAGCGACCGGAGATTGGCGGGAC-3',
with plasmid pCPURTK13 as a template (17), and
ligated into the HindIII site of the intermediate
plasmid popA10L to create the final VV transfer vector popA10L-gpt. The fidelity of the PCR-amplified gene
fragments was confirmed by sequencing. The strategy for construction of the transfer vector popA10L-gpt is illustrated in Fig.
1.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Construction of the conditional VV recombinant
VVindA10L. A DNA fragment corresponding to nucleotides 1 to 570 of the
A10L ORF was amplified from VV genomic DNA by PCR using primers 1 and 2 and cloned into pUC118. Another DNA fragment, consisting of a 21-bp
E. coli lacI operator (op) sequence, the promoter region
between the A10L and A11R genes, and 457 bp of the A11R ORF, was
synthesized by PCR amplification using primers 3 and 4 and subsequently
cloned into pUC118 carrying the A10L DNA fragment. The sequence around
the A10L promoter is shown with A10L and A11R translation initiation
codons in boldface, lac operator in lowercase,
SmaI restriction site in italics, and TAAAT
consensus sequence for late gene expression underlined. The E. coli gpt ORF under the control of the VV p7.5 early/late promoter
was cloned to the intermediate plasmid popA10L to generate the transfer
vector popA10L-gpt. This plasmid was used to transfect
BSC-40 cells infected with VVlacI, which constitutively expresses the
E. coli lac repressor. Transient dominant selection was used
to isolate the VVindA10L recombinants in the presence of 5 mM IPTG.
Sequences of the primers used are given in Materials and Methods.
|
|
Recombinant virus construction.
VVindA10L was isolated by
transient dominant selection as previously described (16,
66). All steps of the purification, isolation, and propagation
of lac repressor-regulated mutant viruses were carried out
in the presence of 5 mM IPTG. Briefly, the targeting plasmid
popA10L-gpt was transfected into BSC-40 cells infected with
VVlacI, which constitutively expresses the lacI repressor (42). Selection of the gpt-carrying
recombinants was performed in the presence of mycophenolic acid (MPA;
25 µg/ml) and IPTG (5 mM). The intermediate recombinant virus, which
contains two copies of the A10L gene, was plaque purified two times in
the presence of MPA and IPTG. The following two rounds of purification were performed without MPA selection, which results in the resolution of either VVlacI or VVindA10L where the gpt gene is deleted.
The lac operator-containing plaques were distinguished from
the parental virus by PCR screening using oligonuclotide primers
5'-GTCGCATACTTTGTAATCTAG-3' (nucleotides 161 to 141 of A10L)
and 5'-ACTACGGCGGCATTATGTTCT-3' (nucleotides 94 to 114 of
A11R). The VVindA10L recombinants were subjected to three additional
rounds of plaque purification and amplified to produce the virus stocks
for subsequent experiments.
VVindA10L growth curves.
Confluent monolayers of BSC-40
cells were infected with WR VV or recombinant virus VVindA10L at
multiplicities of infection (MOI) of 2.5 and 0.25 PFU/cell. The
inoculum was removed after 1 h incubation at 37°C, and the cells
were washed twice with DMEM and overlaid with fresh DMEM supplemented
with 2% newborn calf serum and containing or lacking IPTG (5 mM).
Cells were collected at the indicated times after infection at high or
low MOI, and virus yields (PFU per milliliter) were determined by
titration on BSC-40 cells in the presence of 5 mM IPTG. To determine
the VVlacI input, parallel cultures were maintained at 4°C for the 1-h adsorption period, after which cells were washed twice with DMEM
and collected.
Metabolic labeling.
BSC-40 cells were infected (5 PFU/cell)
with VVlacI or VVindA10L in the presence or absence of 5 mM IPTG. At
different times postinfection, cells were washed with methionine-free
DMEM and incubated in the same medium for 30 min to deplete
intracellular methionine. Cells were then pulse labeled with
[35S]methionine (50 µCi/ml) for 30 min, washed three
times with ice-cold phosphate-buffered saline (PBS), collected, and
lysed in 1× sample buffer (62.5 mM Tris [pH 6.8], 2% sodium dodecyl
sulfate [SDS], 0.25% bromophenol blue, 5% glycerol, 5%
2-mercaptoethanol). Samples were boiled for 5 min, and proteins were
fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a nitrocellulose membrane. Labeled proteins were
visualized after autoradiography.
Western blot analysis.
Viral proteins from purified virions
or extracts from virus-infected cells were fractionated by SDS-PAGE,
transferred to nitrocellulose, and incubated with different antibodies
specific to VV proteins. After incubation with a peroxidase-conjugated
secondary antibody, immunoreactive bands were detected either by color
development after incubation with chloronaphtol as described elsewhere
(42) or by chemiluminescence (ECL kit; Amersham).
DNA analysis of purified virions.
Viral particles from WR VV
and VVindA10L were purified by centrifugation through a 45% sucrose
cushion and banding on 20 to 45% sucrose gradient. Purified virions
were pelleted and resuspended in 1 mM Na2HPO4
buffer, and the number of particles was determined by measuring the
optical density of virus preparations (1 unit of optical density at 260 nm is equivalent to 1.2 × 1010 particles/ml
[23]). The protein content in these samples was determined by the Bradford assay using a bicinchoinic acid kit (Pierce). Viral suspensions containing approximately the same amount of
viral particles were prepared in PBS. Twofold dilutions made from these
starting virus suspensions were applied in duplicate to nitrocellulose
membranes in a vacuum manifold. One of the membranes was incubated with
anti-VV antibodies in 5% BLOTTO followed by incubation with
peroxidase-conjugated goat anti-rabbit immunoglobulin G. Antibody
reactivity was detected by chemiluminescence. The twin membrane was
blotted on paper filter saturated with 0.5 M NaOH, then on paper
saturated with 1 M Tris-HCl (pH 7.5)-1.5 M NaCl, and finally on paper
saturated with 2× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium
citrate. The viral DNA was UV cross-linked to the membrane and
hybridized with a probe prepared by 32P labeling of
purified VV DNA. Hybridization was carried out by standard procedures.
The radioactive DNA signal was visualized by autoradiography.
Electron microscopy. (i) Negative staining of purified
virions.
Suspensions of purified WR VV and VVindA10L IMVs were
treated as described elsewhere (44). Virions were adsorbed
to electron microscopy grids coated with collodion and carbon and made
hydrophilic by glow discharge. After washing in distilled water,
samples were stained with a 2% solution of uranyl acetate for 30 s, allowed to dry, and studied by electron microscopy.
(ii) Embedding of infected cells and isolated virions in
EML-812.
Monolayers of HeLa cells were infected at an MOI of 5 PFU/cell with WR VV or VVindA10L in the presence or absence of IPTG. At
24 h postinfection (hpi), cells were fixed in situ with
a mixture of 2% glutaraldehyde and 1% tannic acid in 0.4 M HEPES
buffer (pH 7.5) for 1 h at room temperature. Suspensions of
purified WR VV or VVindA10L virions were fixed with the same mixture
under identical conditions. Fixed monolayers were removed from the
culture dishes in the fixative and transferred to Eppendorf tubes.
After centrifugation and washing with HEPES buffer, the cells or the virions were processed for embedding in the resin TAAB 812 (TAAB Laboratories Ltd., Berkshire, United Kingdom) as previously described (39, 40, 47). Ultrathin (around 30-nm) sections of the
samples were obtained and stained with saturated uranyl acetate and
lead citrate by standard procedures.
(iii) Embedding of infected cells in Lowicryl K4M for immunogold
labeling.
Infected cells were submitted to a mild fixation in situ
with a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde in PBS
(pH 7.4) for 30 min at 4°C. Cells were removed from the culture dishes in the fixative, centrifuged, and washed with PBS to be processed for embedding in Lowicryl K4M at room temperature as previously described (39, 46, 48). Ultrathin sections were collected on gold grids coated with Formvar and carbon and processed for immunogold detection of VV proteins as previously described in
detail (46).
(iv)Detection of DNA on ultrathin sections.
For DNA
detection, freshly obtained sections of infected cells embedded in
Lowicryl K4M were used. Sections were treated for conventional
immunogold labeling using a monoclonal antibody specific for
single-stranded and double-stranded DNA (Chemicon International, Inc.,
Temecula, Calif.) diluted 1:300 in Tris buffer-gelatin (30 mM Tris-HCl
[pH 8.0] containing 150 mM NaCl, 0.1% bovine serum albumin, and 1%
gelatin) and a gold conjugate of goat anti-mouse and 10-nm colloidal
gold particles according to standard immunogold procedures (39,
48). DNA on the surface of the sections was also detected as
described by Bendayan (1), using a conjugate of DNase I
and colloidal gold particles of 10 nm (E-Y Laboratories, Inc., San
Mateo, Calif.). Sections were preincubated for 15 min with PBS (pH 6.0)
containing 0.02 mg of polyethylene glycol 8000 (PEG) per ml (PBS-PEG).
Samples were then treated with DNase-gold (diluted 1:5 in PBS-PEG, pH
6.0) for 1 h and washed with PBS-PEG (six times for 5 min each).
After fixation with glutaraldehyde (2.5% in PBS-PEG) for 10 min and
washing with distilled water (five times for 2 min each), sections were
stained with saturated uranyl acetate for 25 min, washed with water,
and dried. Some sections were pretreated with nonconjugated DNase I (1 mg/ml) 1 h at 37°C, washed with water, and dried before
incubation with PBS-PEG and DNase-gold. Samples were studied in a JEOL
1200 EX II electron microscope.
 |
RESULTS |
Construction of a recombinant VV with an inducible A10L gene.
P4a, the product of the A10L ORF, is the major structural core
polypeptide of VV (49). Its proteolytic processing is
believed to be essential for the production of infectious mature virus particles. However, the possible functions of the precursor form P4a or
its cleavage products 4a (62 kDa) and 23-kDa proteins have not been
studied. To investigate the role(s) of these polypeptides in the virus
life cycle and morphogenesis, we constructed and characterized an
inducible VV recombinant, VVindA10L, in which the synthesis of P4a is
under the control of the E. coli lacI operator-repressor
system. The standard method where by the lac operator
sequence is placed adjacent to the promoter of the target gene
(66, 68) was used in this work. Briefly, VVindA10L was generated starting with recombinant virus VVlacI, containing in the
nonessential thymidine kinase locus of VV genome the lacI repressor gene driven by the VV constitutive p7.5 promoter
(42). Plasmid popA10L-gpt, containing (i) the
lac operator between the endogenous promoter and the
initiation codon ATG for A10L and (ii) the p7.5-regulated E. coli
gpt gene for transient dominant selection of the viral
recombinants (16, 61), was generated by recombinant PCR
and transfected to VVlacI-infected cells. The strategy followed to
construct the operator-controlled A10L gene is depicted in Fig. 1. Two
successful homologous recombination events resulted in the replacement
of endogenous A10L gene with the mutated copy and deletion of the
gpt marker gene. DNA samples from 43 individual plaque
isolates were screened by PCR for the presence of the lac
operator, using primers flanking the site of insertion. The sizes of
the PCR products for the wild-type (WT) and lac
operator-mutated forms of the A10L gene were 289 and 310 bp,
respectively (data not shown). Nine (21%) of the 43 samples analyzed
were found to contain the 21-bp operator sequence, 12 (28%)
corresponded to the parental virus, and 22 (51%) contained both forms
of the PCR product. These were interpreted to represent single-crossover recombination intermediates where two copies of the
A10L gene are arranged in tandem. Several of the operator-containing inducible mutants were plaque purified two or three additional times,
and virus from these plaques was amplified in the presence of 5 mM IPTG
to produce virus stocks. As determined by PCR, the mutant A10L viruses
were found free of parental VVlacI virus.
IPTG-dependent expression of the A10L gene.
To ensure that
A10L gene expression was regulated by IPTG, BSC-40 cells were infected
with the mutant virus VVindA10L or with the parental virus VVlacI in
the absence or presence of IPTG. At 24 hpi, cells were collected and
cell extracts were analyzed by Western blotting with anti-P4a
antibodies. As shown in Fig. 2A, the P4a
precursor and its cleavage product 4a were clearly observed in extracts
from cells infected with VVindA10L in the presence of IPTG (lane 3),
although the level of A10L gene expression was lower than in cells
infected with WR VV (lanes 1 and 2) or VVlacI (lanes 5 and 6) with or
without IPTG, and cleavage of the P4a precursor was also diminished. On
the other hand, in cells infected with VVindA10L in the absence of
IPTG, P4a and 4a proteins can be barely detected (lane 4). The minimal
expression of these proteins under these conditions may be due to the
presence in the virus stock of a minor amount of mutant viruses that
escape lac operator repression (discussed below).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 2.
Inducible expression of P4a in VVindA10L-infected cells.
BSC-40 cells were infected (5 PFU/cell) with WR (lanes 1 and 2),
VVindA10L (lanes 3 and 4), or VVlacI (lanes 5 and 6) in the presence or
absence of IPTG, as indicated at the top. At 24 hpi, cells were
harvested, and proteins were separated by SDS-PAGE (10% polyacrylamide
gel) and transferred to a nitrocellulose membrane. The membrane was
excised in two parts; the upper one was reacted with anti-P4a/4a
antibodies (A), and the lower one was incubated with anti-39K
antibodies (B). Protein bands were developed by chemiluminescence after
incubation with a secondary peroxidase-conjugated goat anti-rabbit
serum. Positions of the P4a, 4a, and 39K proteins are indicated at the
right side.
|
|
When the same blot was developed with an antibody to the VV 39K
protein, similar amounts of this protein were detected in
extracts from
cells infected with VVindA10L, WR, or VVlacI (Fig.
2B), indicating that
the observed differences in A10L gene expression
were not due to an
overall reduction in viral protein
synthesis.
Replication of VVindA10L under permissive and nonpermissive
conditions.
To determine the possible effect of A10L gene
repression on virus replication and cell-to-cell spread, we compared
plaque formation by VVindA10L in the presence and absence of the
inducer IPTG with that by the parental virus VVlacI. Figure
3A shows that omission of IPTG after
infection with VVindA10L resulted in a marked reduction, of about 95%,
in the number of plaques with respect to the values obtained when
infections were carried out under permissive (with IPTG) conditions.
Moreover, while plaques made by VVindA10L in the presence of the
inducer were all slightly smaller than those produced by the parental
virus, in cells infected by the mutant in the absence of IPTG, small
and large plaques were formed. Large plaques are probably due to some
repressor escape mutants that arise during VVindA10L infection under
restrictive conditions, as has been indicated for other VV-inducible
mutants (43, 47, 61, 68). In addition, we have determined
viral yields after infection at both high (2.5 PFU/cell) and low (0.25 PFU/cell) MOI. Titration of virus from cells infected for 24 h with 2.5 PFU of VVindA10L per cell in the absence of IPTG showed a reduction of
virus yields of about 2 log units compared to VVlacI-infected cells
(Fig. 3B). In the presence of the inducer, virus yields were only
partially recovered. Under these conditions, the maximum titer was
reached at 24 hpi, and it was more than 1 log lower than VVlacI titers.
This result is in accordance with the smaller plaque size phenotype
displayed by the mutant. In addition, when infection of cell cultures
was performed at a low MOI, the yield obtained by 24 hpi in the
presence of the inducer was more than 2 log units higher than the yield
attained when IPTG was omitted (Fig. 3C). Moreover, the progeny virus
grown under these nonpermissive conditions was shown to escape
regulation by IPTG, since the same titers were obtained when titrations
were performed in the presence or absence of the inducer (not shown).
Again, this result indicates that in the VVindA10L stock there is a
minor population of virus that escape lacI repression. From
the growth characteristics of VVindA10L, we can conclude that the A10L
gene product is essential during the virus life cycle.


View larger version (119K):
[in this window]
[in a new window]
|
FIG. 3.
VVindA10L virus growth is dependent on the presence of
IPTG. (A) Plaque assay. Confluent monolayers of BSC-40 cells were
infected with 10-fold dilutions of either VVlacI or VVindA10L stocks
and overlaid with DMEM supplemented with 2% newborn calf serum and
containing or lacking 5 mM IPTG. After 2 days, the monolayers were
stained with 1% crystal violet. (B) One-step growth curves. BSC-40
cells were infected at an MOI of 2.5 PFU/cell with VVlacI or VVindA10L
in the presence or absence of 5 mM IPTG. (C) Multiple-step growth
curves. BSC-40 cells were infected at an MOI of 0.25 PFU/cell with
VVindA10L in the presence or absence of 5 mM IPTG. Cells infected at
high or low MOI were harvested just after the adsorption (1-h time
point) or at various times postinfection (8, 24, and 48, hpi), and
progeny viruses were titrated by plaque assay on monolayers of BSC-40
cells in the presence of IPTG. The titer of VVlacI at time zero
corresponds to the virus remaining after a 1-h adsorption period at
4°C.
|
|
Viral protein synthesis in cells infected with VVindA10L.
To
examine whether repression of the A10L gene has any effect on the
pattern and/or the timing of viral protein synthesis, cells infected
with VVindA10L in the absence or presence of the inducer were
pulse-labeled with [35S]methionine for 30 min at
different times postinfection. As shown in Fig.
4A, both in the absence and in the
presence of IPTG, there was a delay in the appearance of viral proteins
and the concomitant shutoff of host protein synthesis compared with
extracts of cells infected with the control virus VVlacI. While in
VVlacI-infected cells late proteins were clearly visible by 6 hpi (lane
8), it took 8 h to first visualize some of these proteins in cells
infected with the mutant virus (lanes 12 and 13), and the increase in
the amount of these proteins was most obvious at 24 hpi. Thus, despite the initial delay, by 24 hpi the rate of protein synthesis appeared to
be similar in VVlacI- and mutant-infected cells (compare lanes 14 to
16). The profile of proteins synthesized in VVindA10L-infected cells in
the presence or absence of the inducer were almost indistinguishable except for the absence in the latter case of a band corresponding in
size to P4a and the reduced amount of a protein that was later identified by Western blotting as the 4b cleavage product (see below).
These two products were also reduced in amount in proteins synthesized
in cells infected by VVindA10L under permissive conditions compared
with VVlacI-infected cells (compare lanes 14 and 15). In cells infected
with the mutant, with or without IPTG, there were three additional
bands which were not detected in VVlacI-infected cells.

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 4.
Synthesis of viral proteins. BSC-40 cells were infected
(5 PFU/cell) with VVlacI or VVindA10L in the presence or absence of 5 mM IPTG. At different times postinfection (indicated below panel A),
cells were pulse-labeled with [35S]methionine (50 µCi/ml) for 30 min. A lysate from 35S-labeled uninfected
cells (U) was included as a control. Proteins were fractionated by
SDS-PAGE (10% polyacrylamide gel) and transferred to a nitrocellulose
membrane. (A) 35S-labeled proteins were visualized after
autoradiography of the nitrocellulose membrane. (B) Western blot
analysis of the transferred proteins with antibodies against the P4a,
P4b, VP8, 39K, and 65K proteins.
|
|
To identify some of the radioactive proteins after separation by
SDS-PAGE, proteins were transferred to nitrocellulose and
probed in
Western blot analysis with different antibodies to VV
proteins P4a,
P4b, VP8, 39K, and p65 (D13L). Surprisingly, while
in cells infected
with VVlacI most proteins could be first detected
by 6 hpi (Fig.
4B,
lane 8), in VVindA10L-infected cells all proteins
assayed were present
at any time postinfection, even at the earliest
time point tested (2 hpi) (lanes 3 and 4), and the amount of each
of these proteins did not
increase over the time until 8 or 24
hpi, when there was a clear
enhancement in the intensity of the
corresponding protein bands. Since
the proteins analyzed are all
components of the viral particle, their
presence from the beginning
of the infection indicates that a large
amount of the input virus
remained associated with the cells. With the
anti-P4a antibodies
(blot a), we confirmed that by 24 hpi only a minor
amount of this
protein was accumulated in cells infected with the
mutant without
IPTG (lane 16), but the protein was readily synthesized
when IPTG
was added (lane 15), although both the total amount of
protein
and the rate of proteolytic processing of the P4a precursor
were
reduced compared with cells infected with the parental virus (lane
14). The bands corresponding to P4b and 4b products were also
identified after reactivity with the specific antibody (blot b).
In the
autoradiogram, the 4b cleavage product was not discernible
among the
proteins synthesized at 24 hpi in cells infected with
the mutant in the
absence of IPTG (Fig.
4A, lane 16), and a reduced
amount of this
product was observed when infection was performed
in the presence of
IPTG (lane 15) compared with the amount detected
in extracts from
VVlacI-infected cells (lane 14). This result
suggests that proteolytic
processing of P4b was very inefficient
in cells infected by the mutant
without IPTG (lane 16) and still
poorly efficient in the presence of
the inducer. Similarly, cleavage
of VP8 precursor was somewhat
inhibited in cells infected with
the mutant plus IPTG, and less
processing was observed in the
absence of IPTG (compare lanes 14 to 16 in Fig.
4B, blot
c).
The 39K and 65K proteins were also present in VVindA10L-infected cells
from the first time point postinfection tested, and
the amount of these
two products began to increase by 6 to 8 hpi
(blots d and
e).
Thus, from this experiment we conclude that A10L gene expression is not
essential for viral protein synthesis but is required
for proteolytic
processing of the two other major core proteins,
P4b and
VP8.
VV morphogenesis is interrupted when synthesis of the A10L gene is
repressed.
The lethal phenotype displayed by VVindA10L under
nonpermissive conditions and the inefficient proteolytic processing of
the major core precursors are both indicative of a blockade in virion morphogenesis. Thus, we examined by electron microscopy thin sections of cells infected with VVindA10L in the presence and absence of IPTG.
Empty, spherical IV-like virions, as well as aberrant IV particles with
very dense internal material, accumulate in the cytoplasm
of HeLa cells
infected with the VVindA10L recombinant virus. Neither
normal IVs nor
IMVs were detected, and large dense aggregates
that
organize in bands accumulated in the cytoplasm of
these cells
(Figs.
5B,
6A, and
6B). Similar,
though smaller, aggregates are
also occasionally seen in HeLa cells
infected with WR VV at long
postinfection times (not shown). In the
presence of IPTG, characteristic
IVs coexist with empty or abnormal
IV-like particles. In this
case, IMV-like virions were able to form,
although most of them
were round (Fig.
5D and
6). Interestingly, dense
material entering
IVs is also frequently seen (Figs.
5C and
6B). These
results strongly
suggest that the organization of the IV content is
clearly disturbed
in this mutant, while the process of envelope
formation is indistinguishable
from that observed in WR VV-infected
cells. Immunogold detection
of VV proteins also points to this fact.
While the envelope proteins
21K (A17L), 15K (A14L), and 65K localized
in the viral crescents
or in the envelope of IV-like particles (Fig.
7), the core protein
VP8 was almost
absent, as indicated by immunogold labeling on
sections (Fig.
8). Signal associated with the 39K
protein was
variable in IV-like particles. Scattered labeling around
viral
particles was also detected (Fig.
8A and
8B). Although
differences
between the samples with IPTG and without IPTG were not
dramatic,
labeling in the latter was more heterogeneous, with a higher
percentage
of IV-like particles exhibiting no signal. Regarding the 14K
(A27L)
envelope protein, it has been previously shown that in the
absence
of virion assembly the protein is dispersed throughout the
cytoplasm
(
44), and in normal infections this protein can
be first seen
associated with viral membranes at a transition stage of
virion
assembly between IV and IMV (
53). Thus, it is not
surprising
the scattered distribution of this protein in the cytoplasm
of
VVindA10L infected cells where it also localizes in cytoplasmic
aggregated material (Fig.
7D).


View larger version (294K):
[in this window]
[in a new window]
|
FIG. 5.
Low-magnification fields of HeLa cells infected
for 24 h with VVindA10L in the absence (A and B) or presence (C
and D) of IPTG. The cytoplasm of cells infected with VVindA10L in the
absence of IPTG shows areas that exclude cellular organelles with
electron-dense spots (double arrows in panel A) and spherical IV-like
structures. Some of these are similar to IVs but apparently devoid of
electron-dense viroplasmic material (asterisks), while some others are
clearly different and contain very dense material or membranous
structures (arrows). When HeLa cells are infected with VVindA10L in the
presence of IPTG, characteristic IVs together with IV-like particles
are seen (asterisks mark empty IVs, while arrows point to IVs
containing membranes or very dense material). Cytoplasmic very dense
filamentous structures (arrowheads) and round IMV-like particles
(marked IMV*) can be also distinguished. N, nucleus; bars, 0.5 µm.
|
|

View larger version (153K):
[in this window]
[in a new window]
|
FIG. 6.
High-magnification fields of different types of viral
particles formed in HeLa cells infected for 24 h with VVindA10L in
the presence of IPTG (A to C) or with WR VV (D). (A and B)
Characteristic IVs are seen near numerous IV-like particles of abnormal
content. Very electron-dense material (arrowheads) that organizes in
regularly spaced bands accumulates in the cytoplasm and can also be
seen inside IV-like particles (arrows). (C) IMV-like particles (marked
IMV*) formed in these cells contain a dense core and have an abnormal
round shape compared with WR VV IMVs (D). Bar, 200 nm.
|
|

View larger version (147K):
[in this window]
[in a new window]
|
FIG. 7.
Immunogold labeling of VV envelope proteins in HeLa
cells infected with VVindA10L in the absence of IPTG. Rabbit polyclonal
antisera and a conjugate of secondary antibody and colloidal gold (10 nm) were used (see Materials and Methods) to localize 65K (A), 15K (B),
21K (C), and 14K (D) proteins, the products of genes D13L, A14L, A17L,
and A27L, respectively. (A to C) In all cases, labeling is mainly
concentrated in the curved crescents of IV-like particles (small
asterisks), with no labeling associated to the very dense material of
regular bands (arrowhead). (D) The 14K protein seems to form
cytoplasmic accumulations (large asterisk), and only a few IV-like
particles present a weak peripheral signal (arrows). Bar, 200 nm.
|
|

View larger version (103K):
[in this window]
[in a new window]
|
FIG. 8.
Immunogold detection of VV core proteins in HeLa
cells infected with VVindA10L in the presence (A, C, and E) or absence
(B, D, and F) of IPTG. Rabbit polyclonal antisera and a conjugate of
secondary antibody and colloidal gold (10 nm) were used to localized
39K (A and B), P4a (C and D), and VP8 (E and F), the products of genes
A4L, A10L, and L4R, respectively. (A) Labeling associated with 39K is
seen scattered in the cytoplasm and inside IVs (arrows). A weak
labeling associated to the very dense cytoplasmic bands is also usually
seen (arrowhead). (B) IV-like particles formed in the absence of IPTG
(asterisks) contain a variable amount and distribution pattern of gold
particles. Labeling associated with P4a is weak in the viral particles
formed in the presence of IPTG (arrow in panel C) and absent both in
the very dense cytoplasmic bands (arrowhead in C) and in IV-like
particles formed in the absence of IPTG (asterisks in panel D). The VP8
nucleoprotein localizes inside IVs assembled in the presence of IPTG
(arrows in panel E), while IV-like particles formed in the absence of
the inducer (asterisks in panel F) are almost totally devoid of signal.
Bar, 200 nm.
|
|
The strong electron density of the large aggregates seen in the
cytoplasm of VVindA10L-infected cells, together with the fact
that they
appear in most cases in contact with or even inside
IVs (Fig.
5 and
6B), indicates that they may represent nucleoprotein
complexes. To
analyze this possibility, we used either anti-DNA
antibodies followed
by gold-conjugated anti-immunoglobulin G or
directly gold-conjugated
DNase. DNA localization on thin sections
of infected cells provided
clear signals in cellular chromatin
and the interior of IMVs, as well
as in the large, dense aggregates
accumulated in the cytoplasm and the
interior of some IV-like
particles (Fig.
9A to D). The specificity of
the signal is indicated
by the fact that when sections were
preincubated with nonconjugated
DNase for 1 h at 37°C before the
addition of the anti-DNA antibodies
or the DNase-gold, labeling was
precluded (Fig.
9E).

View larger version (113K):
[in this window]
[in a new window]
|
FIG. 9.
DNA localization in HeLa cells infected with
VVindA10L using anti-DNA antibodies or a DNase-gold complex. Lowicryl
K4M ultrathin sections of cells infected with VVindA10L in the presence
(A and B) or absence (C, D, and E) of IPTG were processed for DNA
detection immediately or kept at 4°C until use. Immunogold detection
with a monoclonal anti-DNA antibody labeled the interior of IMV-like
viral particles as well as the large dense aggregates that accumulate
in the cytoplasm and the interior of IVs (A and B). (C and D) A
DNase-gold conjugate of 10 nm also intensively labeled these dense
structures. (E) When sections were pretreated with nonconjugated DNase
(1 h at 37°C), the labeling with anti-DNA or DNase-gold was almost
completely abolished. However, immunogold localization of VV proteins
was not affected by DNase treatment (not shown). Bars, 200 nm.
|
|
However, immunogold localization of VV proteins was not affected by
DNase treatment (not shown). Among the various antibodies
against VV
core or membrane proteins tested, only the anti-39K
antibody provided
weak but repetitive signals in these dense structures
(Fig.
8A). These
results indicate that viral DNA organization
and packaging seem to be
significantly impaired in the absence
of
P4a.
Characteristics of viral particles purified from cells infected
with VVindA10L under permissive conditions.
We have observed that
even in the presence of the inducer VVindA10L, growth is compromised
and low yields of progeny virus are obtained. Moreover, electron
microscopy examination of cells infected under these conditions showed
the presence of a high amount of abnormally rounded IMV-like particles.
The fact that at late times after infection with VVindA10L under
permissive or nonpermissive conditions we still could detect core and
membrane proteins from the input virus, and in large quantity, suggests that these IMV-like particles may not be infectious but may remain attached to the cell membrane. Thus, we examined the characteristics of
particles purified from cells infected with VVindA10L in the presence
of IPTG in comparison with those produced after infection with WR VV
and purified in parallel by banding on sucrose gradients. Similarly
cloudy bands were obtained from both VVindA10L and WR preparations,
although the protein concentration in the WR sample was about double
than that in VVindA10L, indicating that the former contains twice the
amount of particles as the latter. Next, we determined the infectivity
of these preparations by plaque assay in the presence of the inducer.
As the previous result had suggested, the infectivity of VVindA10L
particles was reduced to about 10% with respect to WR. This 10%
infectivity correlates well with the estimated frequency of appearance
of normal brick-shaped IMVs in cells infected by VVindA10L plus IPTG,
as determined by electron microscopy of thin sections from infected cells.
(i) Ultrastructural analysis.
The preparations of purified
virions were also examined by electron microscopy in two ways by
negative staining and in ultrathin section. By negative staining, most
VVindA10L particles were spherical (Fig.
10B), and again, only about 10% showed
the characteristic brick shape of VV. In ultrathin sections, VVindA10L
particles appeared irregularly shaped, although a core-like structure
could be distinguished in the interior (Fig. 10D). By contrast, the
majority (90%) of WR particles purified and handled in parallel showed a typical brick-shaped or ovoid appearance, both by negative staining (Fig. 10A) and in ultrathin sections (Fig. 10C).

View larger version (144K):
[in this window]
[in a new window]
|
FIG. 10.
Morphological characteristics of purified VVIndA10L
IMVs. Suspensions of purified WR VV (A and C) and VVIndA10L (B and D)
virions were processed for negative staining (A and B) or ultrathin
sectioning after embedding in the epoxy resin EML-812 (C and D). (A) By
negative staining, WR VV virions exhibit the characteristic brick
shape, while suspensions of VVIndA10L virions (B) were mainly abnormal
round particles, with a small percentage of normal, brick-shaped
particles (arrow). Insets in panels A and B show representative
negatively stained viral particles at higher magnification. (C and D)
Ultrathin sections of the same viral suspensions show the differences
in shape and internal structure of the two types of virions. VVIndA10L
particles seem to be more sensitive to deformation by the process of
embedding. Particles with abnormal cores and irregular contours were
frequent, while a few were similar to sectioned WR VV particles
(arrow). Insets in panels C and D show representative sectioned viral
particles at higher magnification. Bars, 200 nm.
|
|
(ii) Biochemical analysis.
In an attempt to understand the
basis for the low infectivity of the viral particles produced by
VVindA10L plus IPTG, we analyzed both their DNA content and protein
composition. To determine whether these deficient IMV-like particles
had incorporated the genomic DNA, we performed a slot-blot DNA
hybridization assay. For this, twofold dilutions of the purified virus
preparations from VVindA10L and WR were applied in parallel to
nitrocellulose. Two replicas were generated; one was hybridized with a
32P-probe specific for VV viral DNA, while the other was
reacted with an anti-VV polyclonal serum as a control for the amount of virus loaded. As shown in Fig. 11,
there were no differences in the amount of DNA between VVindA10L and WR
particles. Next, the protein composition of VVindA10L particles was
analyzed by Western blotting in comparison to WR particles. The
patterns of proteins detected by a polyclonal anti-VV serum were very
similar for both preparations, although in VVindA10L there was an
additional high-molecular-weight protein, corresponding in size to the
uncleaved P4a (not shown). The presence of P4a precursor in VVindA10L
purified virions was confirmed after reactivity of the fractionated
virion proteins with specific anti-P4a/4a antibodies (Fig.
12, lane 4). A remnant of P4b precursor
was also detected in purified particles from VVindA10L (lane 2).
Neither P4a nor P4b was detected in the WR preparation (lanes 1 and 3).
This result indicates that the abnormal particles observed in this
preparation may represent intermediate forms in the IV-to-IMV
maturation process.

View larger version (83K):
[in this window]
[in a new window]
|
FIG. 11.
Protein and DNA content of purified virus particles.
Particles were purified from HeLa cells infected with WR or VVindA10L
in the presence of IPTG. Aliquots were analyzed by slot blotting and
reacted in Western blots against a VV polyclonal antiserum (left) or
hybridized with a VV DNA probe (right).
|
|

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 12.
Analysis by western blotting of VVindA10L and WR
purified virions. Viral particles purified from cells infected with WR
(lanes 1 and 3) and VVindA10L (lanes 2 and 4) in the presence of IPTG
by sucrose gradient centrifugation (as described in Materials and
Methods) were loaded (10 µg/lane) in 10% polyacrylamide gels. After
separation by SDS-PAGE, proteins were transferred to a nitrocellulose
membrane and reacted with a polyclonal antiserum against VV (lanes 1 and 2) or against the 4b core proteins (lanes 3 and 4).
|
|
 |
DISCUSSION |
VV particles are complex macromolecular structures that contain
about 100 different polypeptides, including, in addition to structural
proteins, the complete machinery for early gene expression (19,
20, 69). Important and still unresolved issues about VV assembly
are how the full complement of proteins become wrapped by the viral
membrane to generate individual spherical IVs and how the genomic DNA
is incorporated into these particles. Several studies suggested that
the viral DNA packed into a nucleoprotein complex is taken up before
the IVs are completely sealed (13, 18, 28, 31).
Structural proteins localized in the internal core of the mature IMVs
are major components of the viroplasmic matrix of the viral factories
and IVs (57). Thus, it is reasonable to assume that
inhibition of synthesis of any of these proteins will have a major
impact on VV assembly. In the present report, we describe the
generation of a conditional mutant that inducibly expresses the A10L
gene coding for one of the most abundant protein of the virion, P4a.
For this purpose we modified the endogenous A10L gene by introducing
the lac operator sequence between the A10L promoter and the
initiation codon in the context of a recombinant VV that constitutively
expresses the lacI repressor (VVlacI) (42). Mutant viruses (VVindA10L) were selected by the transient dominant selection method (16, 66). By Western blot analysis, we
demonstrated that in cells infected with VVindA10L, the expression of
the P4a precursor and the 4a cleaved product is dependent on the
presence of IPTG in the culture medium. However, even under these
permissive conditions both expression and proteolytic cleavage of P4a
are clearly reduced compared with cells infected with the parental virus VVlacI. This is interpreted as the result of incomplete derepression, since the amount of the 39K core protein used as the
control differed little in both VVindA10L- and VVlacI-infected cultures
with or without IPTG.
The first phenotypic characteristic of VVindA10L observed was the
reduced size of viral plaques. Moreover, the mutant was essentially
unable to form plaques in the absence of the inducer (the number of
plaques produced without IPTG was about 5% of the number produced in
its presence). Reduced viral yields were obtained even in the presence
of the inducer, which indicates that the protein is essential for viral
replication and that the limited amount of this protein produced under
these conditions is not enough to completely restore viral replication.
Thus, addition of IPTG provides semipermissive conditions for VVindA10L
growth. It has been shown for many IPTG-dependent conditional mutants that the level of expression of the lac operator-regulated
gene is lower than WT levels. This lower level of expression of
proteins which are essential for viral replication generally results in reduced viral growth; accordingly, the viral plaques produced by these
conditional lethal mutants in the presence of the inducer are often
smaller than WT plaques (19, 47, 64, 68, 69). Moreover,
using the VOTE expression system, which allows the regulated protein to
be overexpressed, it has been shown that for optimal virus production
of a conditional virus that inducibly express the A5L gene coding for
the 39K core protein, this protein has to be expressed to levels
10-fold higher than those found in a WT infection, suggesting a less
efficient utilization of the protein by the conditional mutant
(63); the same finding has been reported for other
essential proteins (19, 64).
A comparative time course of protein synthesis by labeling infected
cells with [35S]methionine showed a clear delay of about
2 h in the onset of host protein shutoff and the concomitant
appearance of viral polypeptides when cells were infected with the
mutant VVindA10L both under semipermissive and nonpermissive
conditions. However, the pattern of protein synthesized at 24 hpi was
almost identical to that observed in VVlacI-infected cells, although a
reduced amount of P4a was observed when infection with VVindA10L was
performed in the presence of the inducer, and this protein was only
barely detected when IPTG was omitted. The same was true for the 4b
cleaved product. An additional difference is the presence of three
still unidentified polypeptides in cells infected with VVindA10L that were absent in cultures infected with VVlacI. When the same cell extracts were analyzed by Western blotting with antibodies directed against different VV proteins, the most striking result was the presence of the different proteins (P4b, VP8, 39K, and 65K) in all
lanes corresponding to cells infected with VVindA10L, even when
extracts were from cells infected for only 2 h. The most likely
interpretation is that these proteins were remnants of the input virus
used to infect the monolayers. This, in turn, indicates that the
inoculum used contains a high proportion of noninfectious viral
particles. This hypothesis was later verified after purification of
viral particles produced in the presence of IPTG (see below). In
addition, this Western blot analysis confirms the reduced rate of
expression and of proteolytic processing of P4a in cells infected with
VVindA10L in the presence of IPTG; a similar result was obtained for
P4b. The reason for the apparent reduction in the rate of P4b synthesis
remains unknown, although a similar phenomenon was previously described
for the 15K (A14L) membrane protein when synthesis of the 21K (A17L)
protein was repressed (2). The extent of synthesis of VP8,
39K, and 65K proteins by 8 and 24 hpi was similar in cells infected
with VVindA10L as in those infected with VVlacI, indicating that
overall, protein synthesis is not affected by the absence of P4a.
However, proteolytic processing of the core precursor VP8 seems to be
also reduced in cells infected with the mutant virus, an indication
that virion assembly might be blocked. On the other hand, in cells
infected with VVindA10L, synthesis of genomic DNA and processing into
unit-length molecules follow the same kinetics as in cells infected
with the parental VVlacI, as determined by pulsed-field analysis of
viral DNA from cells infected for different periods of time (data not shown). Thus, inhibition of viral replication should occur at a later
step of the virus life cycle.
The analysis of infected cells by electron microscopy confirmed that in
the absence of the P4a protein VV morphogenesis is blocked. Abnormal
IVs together with very electron-dense small aggregates were abundant in
the cytoplasm of cells infected with VVindA10L under nonpermissive
conditions. These aggregates resemble the condensed nucleoid that can
be observed inside many IVs produced in a normal infection.
Electron-lucent IV-like particles devoid of viroplasmic material
coexist with spherical particles filled with dense structures, with the
appearance of parallel layers. No normal IVs nor IMVs were formed in
the absence of P4a protein. Some IV-like particles appear either
enclosing fragments of uncompleted envelopes or partially surrounded by
these membrane fragments. The formation of normal VV forms is recovered
in cells infected with VVindA10L in the presence of IPTG. Normal IVs
enclosing viroplasmic material, IVs with dense nucleoids, and IMVs, all
characteristic forms of a normal infection, are present. Aberrant IVs
like those above described and abnormally rounded IMVs with an
irregular electron-dense core are also seen. In addition, large
regularly arranged electron-dense structures were seen between the
different viral forms. Significantly, some of these dense structures
are observed initiating an encapsidation-like process, suggesting that
they might represent nucleoprotein complexes being taken up by the IVs.
In this regard, immunogold labeling with anti-DNA antibodies and
specific detection with gold-conjugated DNase confirmed the presence of
DNA in these structures. The anti-DNA antibody also provide a clear
signal within the IMV-like particles. Similar regularly spaced dense
elements were previously observed in HeLa cells infected with a
ts mutant (ts6757) generated and characterized by
Dales el al. (8). They also showed the presence of
numerous empty IV-like particles like those that we observe in the
cytoplasm of cells infected with VVindA10L. It would be interesting to
determine the genetic lesion of this ts mutant, which is
probably in the A10L gene, although we cannot discard the possibility
that alterations in other loci may cause the same phenotypic defects.
Collectively, those results show that inhibition of P4a synthesis
interferes with incorporation of viroplasmic matrix by viral envelopes.
An additional conclusion that can be drawn from these results is that
formation of spherical viral envelopes can occur independently of
viroplasm adquisition.
Inhibition of P4a synthesis appears to have no effect on the
distribution of several membrane proteins like 21K, 15K, and 65K, which
are localized on the envelope of the IV-like particles. Under these
conditions the 14K protein, which has been described to associate with
viral particles in a later stage, intermediate between IV and IMV
(53), is seen in cytoplasmic accumulations. A similar
distribution for the 14K protein was observed when VV morphogenesis was
blocked by inhibition of synthesis of the 21K protein
(44). On the other hand, the 39K core protein was present in the IV-like particles produced both in the absence and in the presence of IPTG, although in the absence of the inducer the signal was
more heterogenous, with a higher amount of apparently empty IV-like
particles. Moreover, from the different antibodies tested, only those
raised against this protein provide a weak labeling on the regular
electron-dense structures, suggesting that 39K may form part of the
nucleoprotein complex. However, it remains to be determined whether
antibodies to other VV proteins with DNA-binding capacity may also
label these structures. Weak labeling was observed with antibodies to
P4a and VP8 core proteins in IV-like particles produced in the presence
of the inducer, but those produced in its absence were devoid of
signal. Thus, inhibition of P4a synthesis appears to have a negative
effect on the incorporation into viral particles of VP8 but not of 39K.
Although we have recently shown that during normal infections 39K and
P4a form a stable complex early in morphogenesis (41), the
above result indicates that this interaction is not a requirement for
the incorporation of the 39K protein into IVs. In this regard, it has
been proposed that 39K is a membrane-associated protein, and
interaction of 39K with the 21K membrane protein has been suggested
(5).
Suspensions of purified WR VV and VVindA10L IMVs visualized by negative
staining or sectioned after embedding in resin showed that most of
VVindA10L virions are ovoid or round particles, with a small percentage
of normal, brick-shaped particles. These round particles could
represent abnormal particles but also intermediate maturation stages.
The very low ratio between the number of infective particles and number
of physical particles calculated for VVindA10L suggested that the
particles of abnormal shape could be noninfectious. Adsorption of these
noninfectious particles to cell monolayers would explain the high
abundance of structural proteins in extracts from cells harvested at
early times postinfection as mentioned before. Biochemical analysis of
these particles indicated that their DNA content is normal; however,
although the overall protein profile was almost undistinguishable from
that displayed by WT particles, a significant difference was the
presence of remnants of uncleaved P4a and P4b precursors in VVindA10L
particles. This latter result favors the hypothesis that these
particles are maturation intermediates. On the other hand, the few
characteristic brick-shaped IMVs observed are believed to correspond to
fully rescued VVindA10L particles that would account for the low
infectivity of this preparation, although we cannot discard the
possibility that these normal IMVs could correspond to progeny virus
originated from a minor proportion of operator escape mutants that can
be present in the VVindA10L virus stock and would also account for the
production of the few large plaques produced in the absence of IPTG.
However, we consider this possibility unlikely since characteristic
IMVs were not seen in any of the many cells infected with VVindA10L
under nonpermissive conditions that we have examined by electron microscopy.
As mentioned above, a question that remains to be resolved is the
mechanism of DNA uptake into viral particles. Although it has not been
formally proven, several studies point to the idea that the genomic DNA
is packed into a nucleoprotein complex that became condensed into a
nucleoid-like structure, and it is this structure that enters into
unsealed IVs. The mechanism of nucleoprotein incorporation into IVs was
first suggested by Morgan (31), who illustrated by
electron microscopy the different steps that would result in the
formation of the internal core structure. These images are not
frequently seen by electron microscopy during a normal infection,
suggesting that this would be a very efficient and fast process.
However, certain abortive infections in which VV assembly is blocked
result in the accumulation of large cytoplasmic DNA crystalloids that
have the appearance of densely packed, ordered fibrils (8, 18,
31, 36, 52). Such DNA crystalloids were also seen in cells
infected with a conditional mutant that inducibly expresses the A32
gene and which has been described as a DNA packaging mutant
(4). Most of the viral particles produced in the absence
of the A32 gene product are devoid of DNA, and thus it has been
suggested that this protein is directly or indirectly involved in the
process of DNA uptake. The electron-dense structures that we observe in
the cytoplasm of VVindA10L-infected cells, although resemblancing these
DNA crystalloids, are not as tightly packed, probably due to the
presence of viral proteins associated to the DNA. Thus, it appears that
the block in VVindA10L mutant occurs at a subsequent step, at which
nucleoprotein complexes have already been formed.
In conclusion, in this report we described an inducible mutant for the
core protein P4a and shown that the organization of the viral core and
DNA encapsidation are impaired in the absence of the protein. The
partial rescue of this mutant upon addition of IPTG may be considered
advantageous since it allows visualization of intermediate stages that
in a normal infection could not be observed. Further characterization
of this mutant virus may provide very useful information regarding the
mechanisms of packaging and incorporation of the genomic DNA into viral particles.
 |
ACKNOWLEDGMENTS |
We thank Lluís Montoliu for sharing his expertise in
analyzing DNA samples by pulsed-field gel electrophoresis and Victoria Jimenez and Ana Garzón for expert technical assistance.
This work was supported by grants from the European Union (PL970064) to
M.E. and from the DGICYT of Spain (PB960818) to J.L.C. J.R.R. was
the recipient of a contract from the CSIC of Spain.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular and Cellular Biology, Centro Nacional de
Biotecnología, Consejo Superior de Investigaciones
Científicas, Campus Universidad Autónoma, Cantoblanco,
28049 Madrid, Spain. Phone: 34-91-585-4503. Fax: 34-91-5854506. E-mail:
mesteban{at}cnb.uam.es.
 |
REFERENCES |
| 1.
|
Bendayan, M.
1989.
The enzyme-gold cytochemical approach: a review, p. 117-147.
In
M. A. Hayat (ed.), Colloidal gold: principles, methods, and applications, vol. 2. Academic Press, Inc., San Diego, Calif.
|
| 2.
|
Betakova, T.,
E. J. Wolffe, and B. Moss.
1999.
Regulation of vaccinia virus morphogenesis: phosphorylation of the A14L and A17L membrane proteins and C-terminal truncation of the A17L protein are dependent on the F10 kinase.
J. Virol.
73:3534-3543[Abstract/Free Full Text].
|
| 3.
|
Blasco, R.,
J. R. Sisler, and B. Moss.
1993.
Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene.
J. Virol.
67:3319-3325[Abstract/Free Full Text].
|
| 4.
|
Cassetti, M. C.,
M. Merchlinsky,
E. J. Wolffe,
A. S. Weisberg, and B. Moss.
1998.
DNA packaging mutant: repression of the vaccinia virus A32 gene results in noninfectious DNA-deficient spherical, enveloped particles.
J. Virol.
72:5769-5780[Abstract/Free Full Text].
|
| 5.
|
Cudmore, S.,
R. Blasco,
R. Vincentelli,
M. Esteban,
B. Sodeik,
G. Griffiths, and J. Krijnse-Locker.
1996.
A vaccinia virus core protein, p39, is membrane associated.
J. Virol.
70:6909-6921[Abstract/Free Full Text].
|
| 6.
|
Dales, S., and L. Siminovitch.
1961.
The development of vaccinia virus in Earles L strain cells as examined by electron microscopy.
J. Biophys. Biochem. Cytol.
10:475-503[Abstract/Free Full Text].
|
| 7.
|
Dales, S., and E. H. Mosbach.
1968.
Vaccinia as a model for membrane biogenesis.
Virology
35:564-583[CrossRef][Medline].
|
| 8.
|
Dales, S.,
V. Milovanovitch,
B. G. T. Pogo,
S. B. Weintraub,
T. Huima,
S. Wilton, and G. McFadden.
1978.
Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopy characterization of their phenotypically expressed defects.
Virology
84:403-428[CrossRef][Medline].
|
| 9.
|
Dales, S., and B. G. T. Pogo.
1981.
Biology of poxviruses.
Virol. Monogr.
18:54-64.
|
| 10.
|
Davison, A. J., and B. Moss.
1989.
Structure of vaccinia virus late promoters.
J. Mol. Biol.
210:771-784[CrossRef][Medline].
|
| 11.
|
DeLange, A. M.
1989.
Identification of temperature-sensitive mutants of vaccinia virus that are defective in conversion of concatemeric replicative intermediates to the mature linear DNA genome.
J. Virol.
63:2437-2444[Abstract/Free Full Text].
|
| 12.
|
Demkowicz, W. E.,
J. S. Maa, and M. Esteban.
1992.
Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.
J. Virol.
66:386-398[Abstract/Free Full Text].
|
| 13.
|
Ericsson, M.,
S. Cudmore,
S. Shuman,
R. C. Condit,
G. Griffiths, and J. K. Locker.
1995.
Characterization of ts16, a temperature-sensitive mutant of vaccinia virus.
J. Virol.
69:7072-7086[Abstract].
|
| 14.
|
Essani, K., and S. Dales. S..
1979.
Biogenesis of vaccinia: evidence for more than 100 polypeptides in the virion.
Virology
95:385-394[CrossRef][Medline].
|
| 15.
|
Esteban, M.
1984.
Defective vaccinia virus particles in interferon-treated infected cells.
Virology
133:220-227[CrossRef][Medline].
|
| 16.
|
Falkner, F. G., and B. Moss.
1990.
Transient dominant selection of recombinant vaccinia viruses.
J. Virol.
64:3108-3111[Abstract/Free Full Text].
|
| 17.
|
Garcia, R.,
F. Almazán,
J. M. Rodríguez,
M. Alonso,
E. Viñuela, and J. F. Rodríguez.
1995.
Vectors for the genetic manipulation of African swine fever virus.
J. Biotechnol.
40:121-131[CrossRef][Medline].
|
| 18.
|
Grimley, P. M.,
E. N. Rosenblum,
S. J. Mims, and B. Moss.
1970.
Interruption by rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes.
J. Virol.
6:519-533[Abstract/Free Full Text].
|
| 19.
|
Hu, X.,
L. J. Carroll,
E. J. Wolffe, and B. Moss.
1996.
De novo synthesis of early transcription factor 70-kilodalton subunit is required for morphogenesis of vaccinia virions.
J. Virol.
70:7669-7677[Abstract].
|
| 20.
|
Hu, X.,
E. J. Wolffe,
A. S. Weisberg,
L. J. Carroll, and B. Moss.
1998.
Repression of the A8L gene, encoding the early transcription factor 82-kilodalton subunit, inhibits morphogenesis of vaccinia virions.
J. Virol.
72:104-112[Abstract/Free Full Text].
|
| 21.
|
Ichihashi, Y.,
S. Matsumoto, and S. Dales.
1971.
Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.
Virology
46:507-532[CrossRef][Medline].
|
| 22.
|
Johnson, G. P.,
S. J. Goebel, and E. Paoletti.
1993.
An update on the vaccinia virus genome.
Virology
196:381-401[CrossRef][Medline].
|
| 23.
|
Joklik, W. K.
1962.
The preparation and characteristics of highly purified radioactively labelled poxvirus.
Biochim. Biophys. Acta
61:290-301[Medline].
|
| 24.
|
Kane, E. M., and S. Shuman.
1993.
Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the 17 gene that encodes a virion component.
J. Virol.
67:2689-2698[Abstract/Free Full Text].
|
| 25.
|
Katz, E., and B. Moss.
1970.
Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin.
Proc. Natl. Acad. Sci. USA
66:677-684[Abstract/Free Full Text].
|
| 26.
|
Katz, E., and B. Moss.
1970.
Vaccinia virus structural polypeptide derived from a high-molecular-weight precursor: formation and integration into virus particles.
J. Virol.
6:717-726[Abstract/Free Full Text].
|
| 27.
|
Klemperer, N.,
J. Ward,
E. Evans, and P. Traktman.
1997.
The vaccinia virus II protein is essential for the assembly of mature virions.
J. Virol.
71:9285-9294[Abstract].
|
| 28.
|
Leduc, E. H., and W. Benhard.
1969.
Electron microscopic study of mouse liver infected by ectromelia virus.
J. Ultrastruct. Res.
6:466-488.
|
| 29.
|
Li, J.,
M. J. Pennington, and S. S. Broyles.
1994.
Temperature-sensitive mutations in the gene encoding the small subunit of the vaccinia virus early transcription factor impair promoter binding, transcription activation, and packaging of multiple virions components.
J. Virol.
68:2605-2614[Abstract/Free Full Text].
|
| 30.
|
Merchlinsky, M., and B. Moss.
1989.
Resolution of vaccinia virus DNA concatemer junctions requires late-gene expression.
J. Virol.
63:1595-1603[Abstract/Free Full Text].
|
| 31.
|
Morgan, C.
1976.
The insertion of DNA into vaccinia virus.
Science
193:591-592[Abstract/Free Full Text].
|
| 32.
|
Morgan, C.
1976.
Vaccinia virus reexamined: development and release.
Virology
73:43-58[CrossRef][Medline].
|
| 33.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication, p. 2637-2761.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven, Philadelphia, Pa.
|
| 34.
|
Moss, B., and E. N. Rosenblum.
1973.
Protein cleavage and poxvirus morphogenesis: tryptic peptide analysis of core precursors accumulated by blocking assembly with rifampicin.
J. Mol. Biol.
81:267-269[CrossRef][Medline].
|
| 35.
|
Moyer, R. W., and R. L. Graves.
1981.
The mechanism of cytoplasmic orthopoxvirus DNA replication.
Cell
27:391-401[CrossRef][Medline].
|
| 36.
|
Nagayar, A.,
B. G. Pogo, and S. Dales.
1970.
Biogenesis of vaccinia: separation of early stages from maturation by means of rifampicin.
Virology
40:1039-1051[CrossRef][Medline].
|
| 37.
|
Payne, L. G.
1980.
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.
J. Gen. Virol.
50:89-100[Abstract/Free Full Text].
|
| 38.
|
Ravanello, M. P., and D. E. Hruby.
1994.
Conditional lethal expression of the vaccinia virus LIR myristylated protein reveals a role in virion assembly.
J. Virol.
68:6401-6410[Abstract/Free Full Text].
|
| 39.
|
Risco, C., and J. L. Carrascosa.
1999.
Visualization of viral assembly in the infected cell.
Histol. Histopathol.
14:905-926[Medline].
|
| 40.
|
Risco, C.,
M. Muntión,
L. Enjuanes, and J. L. Carrascosa.
1998.
Two types of virus-related particles are found during transmissible gastroenteritis virus morphogenesis.
J. Virol.
72:4022-4031[Abstract/Free Full Text].
|
| 41.
|
Risco, C.,
J. R. Rodriguez,
J. L. Carrascosa,
M. Esteban, and D. Rodriguez.
1999.
The vaccinia virus 39K protein forms a stable complex with the 4a major core protein.
Virology
265:375-386[CrossRef][Medline].
|
| 42.
|
Rodríguez, D.,
Y. Zhou,
J. R. Rodríguez,
D. Russell,
V. Jimenez,
W. T. McAllister, and M. Esteban.
1990.
Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor using recombinant vaccinia virus vectors.
J. Virol.
64:4851-4857[Abstract/Free Full Text].
|
| 43.
|
Rodríguez, D.,
M. Esteban, and J. R. Rodríguez.
1995.
Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis.
J. Virol.
69:4640-4648[Abstract].
|
| 44.
|
Rodríguez, D.,
C. Risco,
J. R. Rodríguez,
J. L. Carrascosa, and M. Esteban.
1996.
Inducible expression of vaccinia virus A17L gene provides a synchronized system to follow sorting of viral proteins during morphogenesis.
J. Virol.
70:7641-7653[Abstract].
|
| 45.
|
Rodríguez, J. R.,
D. Rodríguez, and M. Esteban.
1992.
Insertional inactivation of vaccinia virus 32K gene is associated with attenuation in mice and reduction of viral entry in polarized epithelial cells.
J. Virol.
66:183-189[Abstract/Free Full Text].
|
| 46.
|
Rodríguez, J. R.,
C. Risco,
J. L. Carrascosa,
M. Esteban, and D. Rodríguez.
1997.
Characterization of early stages in vaccinia virus membrane biogenesis: implication of the 21-kDa and a newly identified 15-kDa envelope protein.
J. Virol.
71:1821-1833[Abstract].
|
| 47.
|
Rodríguez, J. R.,
C. Risco,
J. L. Carrascosa,
M. Esteban, and D. Rodríguez.
1998.
Vaccinia virus A14L gene product is essential for assembly and attachment of viral crescents to virosomes.
J. Virol.
72:1287-1296[Abstract/Free Full Text].
|
| 48.
|
Salanueva, I. J.,
J. L. Carrascosa, and C. Risco.
1999.
Structural maturation of the transmissible gastroenteritis coronavirus.
J. Virol.
73:7952-7964[Abstract/Free Full Text].
|
| 49.
|
Sarov, I., and W. K. Joklik.
1972.
Studies on the nature and location of the capsid polypeptides of vaccinia virions.
Virology
50:579-592[CrossRef][Medline].
|
| 50.
|
Schmelz, M.,
B. Sodeik,
M. Erisson,
E. J. Wolffe,
H. Shida,
G. Hiller, and G. Griffiths.
1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans-Golgi network.
J. Virol.
68:130-147[Abstract/Free Full Text].
|
| 51.
|
Sekiguchi, J., and S. Shuman.
1997.
Novobiocin inhibits vaccinia virus replication by blocking virus assembly.
Virology
235:129-137[CrossRef][Medline].
|
| 52.
|
Sodeik, B.,
G. Griffiths,
M. Ericsson,
B. Moss, and R. W. Doms.
1994.
Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65.
J. Virol.
68:1103-1114[Abstract/Free Full Text].
|
| 53.
|
Sodeik, B.,
S. Cudmore,
M. Ericsson,
M. Esteban,
E. G. Niles, and G. Griffiths.
1995.
Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus.
J. Virol.
69:3560-3574[Abstract].
|
| 54.
|
Van Meir, E., and R. Wittek.
1988.
Fine structure of the vaccinia virus gene encoding the precursor of the major core protein 4a.
Arch. Virol.
102:19-27[CrossRef][Medline].
|
| 55.
|
VanSlyke, J. K.,
C. A. Franke, and D. E. Hruby.
1991.
Proteolytic maturation of vaccinia virus core proteins: identification of a conserved motif at the N termini of the 4b and 25K virion proteins.
J. Gen. Virol.
72:411-416[Abstract/Free Full Text].
|
| 56.
|
VanSlyke, J. K.,
S. S. Whitehead,
E. M. Wilson, and D. E. Hruby.
1991.
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins.
Virology
183:467-478[CrossRef][Medline].
|
| 57.
|
VanSlyke, J. K., and D. E. Hruby.
1994.
Immunolocalization of vaccinia virus structural proteins during virion formation.
Virology
198:624-635[CrossRef][Medline].
|
| 58.
|
Whitehead, S. S., and D. E. Hruby.
1994.
Differential utilization of a conserved motif for the proteolytic maturation of vaccinia virus proteins.
Virology
200:154-161[CrossRef][Medline].
|
| 59.
|
Whitehead, S. S.,
N. A. Bersani, and D. E. Hruby.
1995.
Physical and molecular genetic analysis of the multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein.
J. Gen. Virol.
76:717-721[Abstract/Free Full Text].
|
| 60.
|
Wilcock, D., and G. L. Smith.
1994.
Vaccinia virus core protein VP8 is required for virus infectivity but not for core protein processing or for INV and EEV formation.
Virology
202:294-304[CrossRef][Medline].
|
| 61.
|
Wilcock, D., and G. L. Smith.
1996.
Vaccinia virions lacking core protein VP8 are deficient in early transcription.
J. Virol.
70:934-943[Abstract].
|
| 62.
|
Wittek, R.,
B. Richner, and G. Hiller.
1984.
Mapping of the genes coding for the two major vaccinia virus core polypeptides.
Nucleic Acids Res.
12:4835-4848[Abstract/Free Full Text].
|
| 63.
|
Williams, O.,
E. J. Wolffe,
A. S. Weisberg, and M. Merchlinsky.
1999.
Vaccinia virus WR gene A5L is required for morphogenesis of mature virions.
J. Virol.
73:4590-4599[Abstract/Free Full Text].
|
| 64.
|
Wolfe, E. J.,
D. M. Moore,
P. J. Peters, and B. Moss.
1996.
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis.
J. Virol.
70:2797-2808[Abstract].
|
| 65.
|
Yang, W.,
S. Kao, and W. R. Bauer.
1988.
Biosynthesis and post-translational cleavage of vaccinia virus structural proein VP8.
Virology
167:585-590[Medline].
|
| 66.
|
Zhang, Y., and B. Moss.
1991.
Inducer-dependent conditional-lethal mutant animal viruses.
Proc. Natl. Acad. Sci. USA
88:1511-1515[Abstract/Free Full Text].
|
| 67.
|
Zhang, Y., and B. Moss.
1991.
Vaccinia virus morphogenesis is interrupted when expression of the gene encoding an 11-kilodalton phosphorylated protein is prevented by the Escherichia coli lac repressor.
J. Virol.
65:6101-6110[Abstract/Free Full Text].
|
| 68.
|
Zhang, Y., and B. Moss.
1992.
Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin.
Virology
187:643-653[CrossRef][Medline].
|
| 69.
|
Zhang, Y.,
B. Y. Ahn, and B. Moss.
1994.
Targeting of a multicomponent transcription apparatus into assembling vaccinia virus particles requires RAP94, an RNA polymerase-associated protein.
J. Virol.
68:1360-1370[Abstract/Free Full Text].
|
Journal of Virology, July 2001, p. 5778-5795, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5778-5795.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jesus, D. M., Costa, L. T., Goncalves, D. L., Achete, C. A., Attias, M., Moussatche, N., Damaso, C. R.
(2009). Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus. J. Virol.
83: 11477-11490
[Abstract]
[Full Text]
-
Gallego-Gomez, J. C., Risco, C., Rodriguez, D., Cabezas, P., Guerra, S., Carrascosa, J. L., Esteban, M.
(2003). Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells. J. Virol.
77: 10606-10622
[Abstract]
[Full Text]
-
Andres, G., Alejo, A., Salas, J., Salas, M. L.
(2002). African Swine Fever Virus Polyproteins pp220 and pp62 Assemble into the Core Shell. J. Virol.
76: 12473-12482
[Abstract]
[Full Text]
-
Chiu, W.-L., Chang, W.
(2002). Vaccinia Virus J1R Protein: a Viral Membrane Protein That Is Essential for Virion Morphogenesis. J. Virol.
76: 9575-9587
[Abstract]
[Full Text]
-
Andres, G., Garcia-Escudero, R., Salas, M. L., Rodriguez, J. M.
(2002). Repression of African Swine Fever Virus Polyprotein pp220-Encoding Gene Leads to the Assembly of Icosahedral Core-Less Particles. J. Virol.
76: 2654-2666
[Abstract]
[Full Text]
-
Risco, C., Rodriguez, J. R., Lopez-Iglesias, C., Carrascosa, J. L., Esteban, M., Rodriguez, D.
(2002). Endoplasmic Reticulum-Golgi Intermediate Compartment Membranes and Vimentin Filaments Participate in Vaccinia Virus Assembly. J. Virol.
76: 1839-1855
[Abstract]
[Full Text]
-
Hung, J.-J., Chung, C.-S., Chang, W.
(2002). Molecular Chaperone Hsp90 Is Important for Vaccinia Virus Growth in Cells. J. Virol.
76: 1379-1390
[Abstract]
[Full Text]